Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults

(2018) Issaka Sagara et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults

(2018) Jessica A. Chichester et al.   VACCINE

New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission

(2017) Kathleen A. McGuire et al.   MALARIA JOURNAL

Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25

(2017) Stephen W. Scally et al.   Nature Communications

Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate

(2017) Andrea J. Radtke et al.   Scientific Reports

The S. aureus 4-oxalocrotonate tautomerase SAR1376 enhances immune responses when fused to several antigens

(2017) Pauline M. van Diemen et al.   Scientific Reports

Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines

(2017) Darren B. Leneghan et al.   Scientific Reports

Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations

(2017) Anais Bompard et al.   Scientific Reports

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

(2016) Muhammed O Afolabi et al.   MOLECULAR THERAPY

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

(2016) Katie Ewer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults

(2016) Alice Minhinnick et al.   VACCINE

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

(2016) Kawsar R. Talaat et al.   PLoS One

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology

(2016) Yuanyuan Li et al.   Scientific Reports

Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

(2015) Christopher A. Green et al.   Science Translational Medicine

The Plasmodium bottleneck: malaria parasite losses in the mosquito vector

(2014) Ryan C Smith et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations

(2014) Domtila Kimani et al.   MOLECULAR THERAPY

Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure

(2014) Sumi Biswas et al.   PLoS One

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS

(2014) Eoghan de Barra et al.   PLoS One

Comparison of field-based xenodiagnosis and direct membrane feeding assays for evaluating host infectiousness to malaria vector Anopheles gambiae

(2013) Louis Clément Gouagna et al.   ACTA TROPICA

Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets

(2013) Simone C de Cassan et al.   Expert Review of Vaccines

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection

(2013) Sean C. Elias et al.   IMMUNOLOGY

Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays

(2013) Kazutoyo Miura et al.   PLoS One

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

(2012) Geraldine A. O’Hara et al.   JOURNAL OF INFECTIOUS DISEASES

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

(2012) Susanne H. Sheehy et al.   PLoS One

Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors

(2011) Susanne H Sheehy et al.   MOLECULAR THERAPY

A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity

(2011) Anna L. Goodman et al.   PLoS One

Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults

(2011) Martha Sedegah et al.   PLoS One

The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species

(2010) Lediya Cheru et al.   VACCINE

The Oligomerization Domain of C4-Binding Protein (C4bp) Acts as an Adjuvant, and the Fusion Protein Comprised of the 19-Kilodalton Merozoite Surface Protein 1 Fused with the Murine C4bp Domain Protects Mice against Malaria

(2008) S. A. Ogun et al.   INFECTION AND IMMUNITY

Effective induction of high-titer antibodies by viral vector vaccines

(2008) Simon J Draper et al.   NATURE MEDICINE

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51

(2008) Yimin Wu et al.   PLoS One